- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
New Leader Proposed for FDA
25 September 2002 (All day)
After 20 months without a leader, the Food and Drug Administration (FDA) may soon have a new commissioner to take the reins. President George W. Bush today named his pick, economist and physician Mark McClellan. The candidate must still be confirmed by Congress, but his prospects look good: He apparently does not have ties to industry, one of the sticking points in appointing a new commissioner.
A Texas native, McClellan, who is just 39, graduated from Harvard and the Massachusetts Institute of Technology. He researched health policy issues at Stanford until relocating to Washington, D.C., where he served from 1998-1999 as President Bill Clinton's deputy assistant treasury secretary for economic policy. He's currently a member of the White House's Council of Economic Advisors. (And McClellan's brother, Scott, is President Bush's deputy press secretary.) "He always brings a ton of energy to projects," says Kathryn McDonald, executive director of the Center for Primary Care in Outcomes Research at Stanford, where McClellan once worked. She recalls his successful efforts to mobilize 70 experts in various disciplines across 17 countries to investigate the economic impact of medical technologies.
McClellan faces a daunting task in running the FDA. The agency is confronting pressure from pharmaceutical and biotechnology companies to streamline and speed up the drug application process, budgetary concerns stemming from relatively stagnant public funding over the last several years, and disputes over subjects ranging from biological warfare to the regulation of genetically modified foods.
McClellan's academic background appears to separate him from industry, a chief concern of some who feared a pro-industry bent at the agency. Senator Edward Kennedy (D-MA), who chairs the Committee on Health, Education, Labor, and Pensions, has lobbied against appointing anyone with ties to pharmaceutical companies. "The senator thinks that McClellan has some outstanding experience," says Jim Manley, a Kennedy spokesperson.
McClellan's home page